Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents

E. Lattmann, S.T. Russell, C.H. Schwalbe, A. Shortt, P.N. Balaram, E. Theochari, M. Alharbi, R. Narayanan, P. Lattmann

Research output: Contribution to journalArticlepeer-review


A new class of 5-arylated 5-hydroxypyrrolones was derived from mucochloric acid in 2 synthetic steps and the chemical structure was confirmed additionally by X-ray analysis. Using a radiolabelled binding assay, potent CCK1 selective ligands were identified (CCK1: 12 nM) and the antagonism was confirmed by using isolated tissue preparations. A series of isobutyl derivatives displayed unsurmountable CCK antagonistic properties and in vitro excellent inhibition of proliferation was obtained in cholecystokinin related cancer cell lines in the nanomolar range. Finally, using xenograft studies in nude mice, two selected pyrrolone derivatives, X = H and X = F a fluorinated analogue (PNB-028), showed a strong inhibition of tumour growth in a chemo-resistant colon cancer-(MAC 16) and a human pancreatic cell line (MIAPACA) at 50 mg kg-1 by oral administration.

Original languageEnglish
Pages (from-to)1138-1145
Number of pages8
Issue number6
Early online date1 Apr 2016
Publication statusPublished - 1 Jun 2016


Dive into the research topics of 'Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents'. Together they form a unique fingerprint.

Cite this